Survival curves for men treated with and without add-on docetaxel converged with longer follow-up. Based on 10 years of trial follow-up data, docetaxel should not be used to treat high-risk localized ...

(RTTNews) - Sagent Pharmaceuticals has recalled two lots of chemotherapy drug Docetaxel Injection, USP due to potential presence of particulate matter from the stopper in the drug, according to the ...

(HealthDay News) — Chemotherapy at the start of androgen-deprivation therapy (ADT) can extend the lives of men with metastatic, hormone-sensitive prostate cancer, according to research published ...

Factors affecting long-term outcomes after postchemotherapy surgery in patients with nonseminomatous germ cell tumors of the mediastinum. Epidermal growth factor receptor (EGFR) targeted therapy in ...

AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals (“Modra”) today announced positive data from its Phase IIb trial evaluating its boosted oral taxane therapeutic, ModraDoc006/r, in patients with ...

A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)." Lung cancer is the ...

Research by a Washington State University-led team of scientists has identified a receptor protein, CHRM1, as a key player in prostate cancer (PC) cells’ resistance to docetaxel (DTX), a chemotherapy ...

Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Hematopoietic Growth Factor PIXY321 After Moderate-Dose Fluorouracil, Doxorubicin, and Cyclophosphamide in Stage II and III Breast ...

Tolmar, Inc. (Tolmar) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Rubraca® (rucaparib), enabling its use prior to chemotherapy for eligible ...

Performing regular liquid biopsies to detect circulating tumour cells (CTCs) could help detect, or even predict, resistance to docetaxel in patients with prostate cancer and allow them to switch them ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Treatment with single-agent sacituzumab govitecan ...